HXP 海西新药 HXPharma

Fujian Haixi Pharmaceuticals Co., Ltd.
福建海西新藥創制股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2637)

POLL RESULTS OF THE 2026 FIRST EXTRAORDINARY GENERAL MEETING HELD ON 4 AUGUST 2026, CHANGE OF EXTERNAL AUDITOR AND APPOINTMENT OF EXECUTIVE DIRECTOR

At the 2026 first extraordinary general meeting (the "**EGM**") of Fujian Haixi Pharmaceuticals Co., Ltd. (the "**Company**") held at Conference Room, Floor 1, Block B, No. 177 Jinda Road, Jianxin Town, Cangshan District, Fuzhou, Fujian Province, the PRC on 4 August 2026 at 10:00 a.m., all the resolutions as set out in the notice of the EGM of the Company dated 15 July 2026 were taken by poll on a one share one vote basis.

The EGM was legally and validly convened in compliance with the requirements of the Company Law of the PRC, the relevant laws and regulations of the PRC, the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Articles of Association. The EGM was chaired by the Mr. Kang Xinshan, the Chairman of the Board.

The poll results of the EGM are as follows:

Ordinary Resolutions		**Number of votes (shares) and percentage in total number of votes (%)**		
		For	**Against**	**Abstain**
1.	To propose the change of external auditor, and to authorise the Board to determine its remuneration	69,189,170 99.9991%	0 0.0000%	600 0.0009%
2.	To propose the appointment of an executive Director	69,189,170 99.9991%	0 0.0000%	600 0.0009%

Notes:

(a) Please refer to the circular of the EGM of the Company dated 15 July 2026 for the full text of the resolutions.

(b) As more than half of the voting rights held by shareholders (including proxies) present at the EGM were cast in favour of each of the resolutions Nos. 1 to 2, such ordinary resolutions were duly passed.

(c) The total number of issued shares of the Company as at the date of the EGM was 78,707,270. The Company did not hold any treasury shares or repurchased shares pending cancellation as at the date of the EGM.

(d) The total number of shares of the Company entitling the holders thereof to attend and vote on resolutions at the EGM was 78,707,270. Shareholders or their proxies holding an aggregate of 69,189,770 shares with voting rights (representing approximately 87.91% of the total number of shares of the Company) attended the EGM.

(e) Tricor Investor Services Limited, the H share registrar of the Company, acted as the scrutineer for the vote-taking at the EGM.

(f) There were no shares entitling the holders thereof to attend and abstain from voting in favour of the resolutions at the EGM as set out in Rule 13.40 of the Listing Rules.

(g) No shareholder was required under the Listing Rules to abstain from voting on any resolution at the EGM.

(h) No shareholder of the Company has stated their intention in the Company's circular dated 15 July 2026 to vote against or to abstain from voting on any of the resolutions at the EGM.

(i) All Directors of the Board of the Company attended the EGM either in person or through video or teleconference.

Change of External Auditor

Reference is made to the Company's announcement dated 15 July 2026 and the circular in relation to the proposed change of external auditor. At the EGM, the shareholders approved the dismissal of Deloitte Touche Tohmatsu and the appointment of RSM China CPA LLP as the external auditor of the Company for the year 2026, and authorised the Board to determine its remuneration.

Change of Director

Mr. Wang Xinkun retired as a Director of the board of directors (the "**Board**") upon the conclusion of the EGM. At the EGM, Mr. Chen Tingze ("**Mr. Chen**") was elected as an executive Director, effective from the conclusion of the EGM until the expiry of the term of the second session of the Board.

The Board would like to express its sincere gratitude to Mr. Wang Xinkun for his valuable contributions to the Company during their tenure. Mr. Wang Xinkun has confirmed that he has no disagreement with the Board and is not aware of any matters in relation to his retirement that need to be brought to the attention of the shareholders.

The Board would like to take this opportunity to welcome Mr. Chen for joining the Board.

By order of the Board
Fujian Haixi Pharmaceuticals Co., Ltd.
Dr. Kang Xinshan
Executive Director, Chairman and General Manager

Hong Kong, 4 August 2026

As of the date of this announcement, the Board comprises (i) Dr. Kang Xinshan, Ms. Feng Yan, Dr. Chen Guangming, Mr. Li Junqing and Mr. Chen Tingze as executive Directors; (ii) Mr. Xu Dong as non-executive Director; and (iii) Ms. Wang Shan Shan, Ms. Pu Meiting and Mr. Lin Bin as independent non-executive Directors.